InterMune files pirfenidone for pulmonary fibrosis in US on mixed data
This article was originally published in Scrip
Executive Summary
InterMune has filed its lead development candidate, pirfenidone, with the US FDA for the treatment of patients with idiopathic pulmonary fibrosis (IPF).